Influenza, COVID-19, and RSV Vaccination Coverage Update

Shannon Stokley
Immunization Services Division
National Center for Immunization and Respiratory Diseases

NAIIS

January 8, 2026

National Immunization Survey-Fall Respiratory Virus Module (NIS-FRVM) methods

- Random-digit-dial cellular telephone survey of adults age ≥18 years in the U.S.
- Respondents are sampled within all 50 states, District of Columbia, five local jurisdictions (Bexar County TX, Chicago IL, Houston TX, New York City NY, and Philadelphia County PA), Puerto Rico and the U.S. Virgin Islands.
- Data are weighted to represent the non-institutionalized U.S. population.
  - Estimates from the NIS-FRVM may differ from estimates based on other data sources.
  - Subject to errors resulting from incomplete sample frame (exclusion of households without cell phones), selection bias (survey respondents may be more likely to be vaccinated than non-respondents), and errors in self-reported vaccination status.
  - Estimates are weighted to selected sociodemographic characteristics of the U.S. population to reduce possible bias from incomplete sample frame and selection bias.
- All responses are self-reported.
- Additional information available at: About the National Immunization Surveys

IQVIA methods

- Measures vaccinations administered at retail pharmacies and American Medical Association (AMA) physicians' medical offices for adults 18 years and older.
- Based on healthcare claims data

Influenza

Influenza vaccination coverage by age group, adults 18 years and older, Behavioral Risk Factor Surveillance System, United States, 2010–2025



Error bars represent 95% confidence intervals around the estimates.

Influenza vaccination coverage and intent among adults ≥18 years by end of December 2025 compared with 2024, NIS-FRVM



- Coverage plus definite intent 12/27/2025: 50.2%
- Coverage plus definite intent 12/28/2024: 48.1%
- Final coverage 2024-25: 46.9%

Influenza vaccination status and intent among adults ≥18 years of age, NIS-FRVM

Key Takeaways/Changes/Summary of Data:

- Among adults aged ≥18 years responding to the National Immunization Survey through December 27, **43.5%** (95% CI: 42.0-45.1) reported having received an influenza vaccine since July 1, 2025.
- Among adults ≥65 years, **67.8%** (95% CI: 62.7-72.9) have received an influenza vaccine since July 1, 2025.

Weekly Influenza Vaccination Status and Intent Among Adults Age ≥18 Years, NIS-FRVM (n = 117,323)



Influenza Vaccination Status and Intent Among Adults Age ≥18 Years by Demographics, NIS-FRVM, December 21–27, 2025 (n = 4,895)



NA: estimate not reported because denominator is <30; AI/AN: American Indian or Alaska Native; NH/OPI: Native Hawaiian or Other Pacific Islander.

Weekly cumulative estimated number of influenza vaccinations administered in retail pharmacies and physician medical offices among adults ≥18 years, 2024–25 and 2025–26 seasons, IQVIA



Influenza vaccination coverage by age group, children 6 months–17 years, United States, 2010–2025, NIS-Flu



Error bars represent 95% confidence intervals around the estimates.

Influenza vaccination coverage and parental intent among children 6 months–17 years by end of December 2025 compared with 2024, NIS-Flu



- Coverage plus definite intent 12/27/2025: 48.5%
- Coverage plus definite intent 12/28/2024: 49.5%
- Final coverage 2024-25: 49.8%

Influenza vaccination status and parental intent among children 6mo-17yrs of age, NIS-Flu

Key Takeaways/Changes/Summary of Data:

- Based on interviews through December 27, **42.5%** (95% CI: 40.1-44.9) of children have received at least one dose of influenza vaccination since July 1, 2025.
- 6.0% (95% CI: 3.8- 8.1) of children have a parent who said they definitely will get their child vaccinated, and 35.2% (95% CI: 30.1-40.3) said they probably or definitely will not get their child vaccinated.
- There are sociodemographic differences in vaccination coverage and intent for vaccination.

Weekly Influenza Vaccination Status and Parental Intent Among Children 6mo-17yrs of Age, NIS-Flu (n = 32,638)



Unvaccinated, probably or definitely will not get vaccinated
Unvaccinated, probably will get vaccinated
Unvaccinated, definitely will get vaccinated
Received at least one influenza vaccine since 7/1/25

Influenza Vaccination Status and Parental Intent Among Children 6mo-17yrs of Age by Demographics, NIS-Flu, December 21–27, 2025 (n = 1,268)



COVID-19

COVID-19 vaccination coverage and intent among adults ≥18 years, by end of December 2025 compared with 2024, NIS-FRVM



- Coverage plus definite intent 12/27/2025: 25.1%
- Coverage plus definite intent 12/28/2024: 29.7%
- Final coverage 2024-25: 23.1%

COVID-19 vaccination coverage and intent among adults ≥65 years, by end of December 2025 compared with 2024, NIS-FRVM



- Coverage plus definite intent 12/27/2025: 43.6%
- Coverage plus definite intent 12/28/2024: 54.6%
- Final coverage 2024-25: 44.6%

Percentage of adults ≥65 years and 18–64 years with high-risk conditions vaccinated with , 2025–2026 COVID-19 vaccine, NIS-FRVM



COVID-19 vaccination status and intent among adults ≥18 years of age, NIS-FRVM

Key Takeaways/Changes/Summary of Data:

- Based on interviews through December 27, **16.6%** (95% CI: 15.6-17.5) of adults ages ≥18 years reported having received a 2025-26 COVID-19 vaccine.
- 8.5% (95% CI: 7.3- 9.7) of adults said they definitely will get vaccinated, and 49.0% (95% CI: 45.7-52.3) said they probably or definitely will not get vaccinated.
- Among adults ≥65 years, **35.2%** (95% CI: 31.9-38.5) have received a 2025-26 COVID-19 vaccine since September 1, 2025.

Weekly COVID-19 Vaccination Status and Intent Among Adults Age ≥18 Years, NIS-FRVM (n = 117,191)



COVID-19 Vaccination Status and Intent Among Adults Age ≥18 Years by Demographics, NIS-FRVM, December 21–27, 2025 (n = 4,882)



NA: estimate not reported because denominator is <30; AI/AN: American Indian or Alaska Native; NH/OPI: Native Hawaiian or Other Pacific Islander.

COVID-19 vaccination coverage and parental intent among children 6 months–17 years by end of December 2025 compared with 2024, NIS-Flu



- Coverage plus definite intent 12/27/2025: 12.6%
- Coverage plus definite intent 12/28/2024: 19.4%
- Final coverage 2024-25: 13.2%

COVID-19 vaccination status and parental intent among children 6mo-17yrs of age, NIS-Flu

Key Takeaways/Changes/Summary of Data:

- Based on interviews through December 27, **7.4%** (95% CI: 6.4- 8.5) of children were up to date with 2025-26 COVID-19 vaccination.
- 5.2% (95% CI: 3.3- 7.1) of children have a parent who said they definitely will get their child vaccinated, and 55.5% (95% CI: 50.4-60.5) said they probably or definitely will not get their child vaccinated.
- The percentage vaccinated was low (below 11%) for children across all sociodemographic groups.

Weekly COVID-19 Vaccination Status and Parental Intent Among Children 6mo-17yrs of Age, NIS-Flu (n = 34,322)



Probably or definitely will not get vaccinated
Probably will get vaccinated or unsure
Definitely will get vaccinated
Received 2025-26 COVID-19 vaccine

COVID-19 Vaccination Status and Parental Intent Among Children 6mo-17yrs of Age by Demographics, NIS-Flu, December 21–27, 2025 (n = 1,339)



RSV

Percentage of adults ≥75 years and 50–74 years with high-risk conditions ever vaccinated with RSV vaccine, 2025–26 season, NIS-FRVM



RSV vaccination status and intent among adults ≥75 years of age, NIS-FRVM

Key Takeaways/Changes/Summary of Data:

- Among adults aged ≥75 years responding to the National Immunization Survey through December 27, **41.7%** (95% CI: 39.4-44.0) reported having ever received an RSV vaccine.
- 6.9% (95% CI: 4.8- 8.9) of adults ≥75 years said they definitely will get vaccinated, and 22.4% (95% CI: 15.8-29.0) said they probably or definitely will not get vaccinated.

Weekly RSV Vaccination Status and Intent Among Adults ≥75 Years, NIS-FRVM (n = 13,827)



Weekly RSV Vaccination Status and Intent Among Adults ≥75 Years by Demographics, NIS-FRVM, December 21–27, 2025 (n = 602)



***Any of the following conditions: chronic lung disease, diabetes with insulin use, heart conditions, immunocompromised, solid organ or blood stem cell transplant, cancer, liver disease, sickle cell disease or thalassemia, or lives in a nursing home.
NA: estimate not reported because denominator is <30; AI/AN: American Indian or Alaska Native; NH/OPI: Native Hawaiian or Other Pacific Islander.

RSV vaccination status and intent among adults 50-74 years of age (high risk***), NIS-FRVM

Key Takeaways/Changes/Summary of Data:

- Among adults aged 50-74 years who are at risk for severe RSV responding to the National Immunization Survey through December 27, **33.1%** (95% CI: 29.7-36.5) reported having ever received an RSV vaccine.
- 16.2% (95% CI: 11.0-21.3) of adults 50-74 years who are at risk for severe RSV said they definitely will get vaccinated, and 24.7% (95% CI: 16.9-32.5) said they probably or definitely will not get vaccinated.

Weekly RSV Vaccination Status and Intent Among Adults 50-74 Years (High Risk***), NIS-FRVM (n = 11,095)



Probably or definitely will not get RSV vaccine
Probably will get RSV vaccine or unsure
Definitely will get RSV vaccine
Received RSV vaccine

Weekly RSV Vaccination Status and Intent Among Adults 50-74 Years (High Risk***) by Demographics, NIS-FRVM, December 21–27, 2025 (n = 478)



***Any of the following conditions: chronic lung disease, diabetes with insulin use, heart conditions, immunocompromised, solid organ or blood stem cell transplant, cancer, liver disease, sickle cell disease or thalassemia, or lives in a nursing home.
NA: estimate not reported because denominator is <30; AI/AN: American Indian or Alaska Native; NH/OPI: Native Hawaiian or Other Pacific Islander.

Protection against RSV and intent for monoclonal antibody among infants <8 months, October–November 2025, NIS-FRVM

Key Takeaways/Changes/Summary of Data:

- Among women aged 18-49 years with an infant born since April 2025 responding to the National Immunization Survey during October 26-November 29, 2025, 3.6% (95% CI: 1.8-5.4) reported the mother received RSV vaccination during pregnancy and their infant did not receive monoclonal antibody, 39.6% (95% CI: 29.7-49.5) reported their infant received monoclonal antibody, 18.3% (95% CI: 11.0-25.5) definitely will get monoclonal antibody for their infant, and 30.3% (95% CI: 19.4-41.3) probably will or were unsure if they will get monoclonal antibody for their infant.



Total infant protection in November 2025 = 43.2%

Summary

- Coverage and intent for influenza vaccination among adults ≥18 years is slightly higher so far this season compared with the same time last season, while coverage among children is similar to last season
- COVID-19 vaccination coverage and intent are lower for children and adults compared to last season
  - Among adults, coverage remains low, hesitancy has increased compared with last season
- RSV coverage ~42% among adults ≥75 years and ~33% among adults 50–74 years with high-risk conditions
- In November 2025, ~43% of eligible infants were protected from RSV by monoclonal antibody or maternal RSV vaccination

Thank you!

sstokley@cdc.gov

For more information visit: RespVaxView | CDC

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov